Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4029243 | 0.84 | CES2 (0.50) | CES2CES1KEAP1CLCN2HDAC4 | |
| SCHEMBL29728646 | 0.83 | KEAP1 (0.53) | CES2CES1KEAP1CLCN2NOTUM | |
| SCHEMBL543572 | 0.83 | KEAP1 (0.53) | CES2CES1KEAP1CLCN2NOTUM | |
| SCHEMBL2560228 | 0.81 | CES2 (0.50) | CES2CES1KEAP1CLCN2HDAC4 | |
| SCHEMBL27835076 | 0.81 | CES2 (0.42) | CES2CES1KEAP1CLCN2NOTUM | |
| SCHEMBL3779540 | 0.79 | CES2 (0.46) | CES2CES1CLCN2HDAC4KDM4E | |
| SCHEMBL7715988 | 0.79 | CES2 (0.79) | CES2CES1KEAP1KDM4E | |
| SCHEMBL1121927 | 0.79 | CES2 (0.48) | CES2CES1KEAP1HDAC4 | |
| SCHEMBL30122043 | 0.79 | NFE2L2 (0.54) | CES2CES1NFE2L2 | |
| SCHEMBL8185535 | 0.79 | NFE2L2 (0.54) | CES2CES1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143251-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110144113-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2011-06-16 | — | — | US | disclosed |
| US-7915408-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2011-03-29 | — | — | US | disclosed |
| CN-101568341-A | Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss | GLAXO GROUP LTD (GB) | 2009-10-28 | — | — | CN | disclosed |
| CN-100413850-C | Chemical compounds | GLAXO GROUP LTD (GB) | 2008-08-27 | — | — | CN | disclosed |
| CN-1391564-A | Chemical compounds | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144113-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | CES2 2294/4885CES1 2484/4885KEAP1 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.